Adverse Occurrence type:
Alerting signals, symptoms, evidence of occurrence:
Fatigue. During days of injections
Demonstration of imputability or root cause:
Definite/probable. Temporal association with GCSF.
Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience
Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program.
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program
Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors
Mobilized blood cells vs bone marrow harvest: experience compared in 171 donors with particular reference to pain and fatigue
Stem cell mobilisation with 16 microg/kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors
Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors
Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience